Matinas BioPharma (MTNB) Reports In-Line Q1 EPS

Matinas BioPharma (NYSE: MTNB) reported Q1 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• HA Sustainable Infrastructure Ca (HASI) PT Lowered to $45 at BofA Securities
• Citi upgrades Bath & Body Works to Buy with $25 price target